70 related articles for article (PubMed ID: 25036774)
1. Nonequivalent response to bromodomain-targeting BET inhibitors in oligodendrocyte cell fate decision.
Chiang CM
Chem Biol; 2014 Jul; 21(7):804-6. PubMed ID: 25036774
[TBL] [Abstract][Full Text] [Related]
2. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
3. Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations.
Shi M; Zheng X; Zhou Y; Yin Y; Lu Z; Zou Z; Hu Y; Liang Y; Chen T; Yang Y; Jing M; Lei D; Yang P; Li X
ACS Omega; 2023 Sep; 8(37):33658-33674. PubMed ID: 37744850
[TBL] [Abstract][Full Text] [Related]
4. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
[TBL] [Abstract][Full Text] [Related]
6. Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.
Mohammed A; Waddell MB; Sutkeviciute I; Danda A; Philips SJ; Lang W; Slavish PJ; Kietlinska SJ; Kaulage M; Sourav D; Ansari AZ
J Am Chem Soc; 2023 Nov; ():. PubMed ID: 37923569
[TBL] [Abstract][Full Text] [Related]
7. Optimization of the synthesis of BET BD2 selective inhibitor XY153.
Zhu R; Li J; Dong R; Hu Q; Chen Z; Chen X; Zhong Z; Xiang Q; Huang C; Lin B; Wu X; Zhang Y; Zhao L; Xu Y
Chem Biodivers; 2024 Feb; 21(2):e202301584. PubMed ID: 38163253
[TBL] [Abstract][Full Text] [Related]
8. From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors.
Koravovic M; Mayasundari A; Tasic G; Keramatnia F; Stachowski TR; Cui H; Chai SC; Jonchere B; Yang L; Li Y; Fu X; Hiltenbrand R; Paul L; Mishra V; Klco JM; Roussel MF; Pomerantz WC; Fischer M; Rankovic Z; Savic V
Eur J Med Chem; 2023 May; 251():115246. PubMed ID: 36898329
[TBL] [Abstract][Full Text] [Related]
9. IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
Wu SY; Lai HT; Sanjib Banerjee N; Ma Z; Santana JF; Wei S; Liu X; Zhang M; Zhan J; Chen H; Posner B; Chen Y; Price DH; Chow LT; Zhou J; Chiang CM
Mol Cell; 2024 Jan; 84(2):202-220.e15. PubMed ID: 38103559
[TBL] [Abstract][Full Text] [Related]
10. Pyronaridine as a Bromodomain-Containing Protein 4-
Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation.
Martella N; Pensabene D; Varone M; Colardo M; Petraroia M; Sergio W; La Rosa P; Moreno S; Segatto M
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979729
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening for myelination promoting compounds using human stem cell-derived oligodendrocyte progenitor cells.
Li W; Berlinicke C; Huang Y; Giera S; McGrath AG; Fang W; Chen C; Takaesu F; Chang X; Duan Y; Kumar D; Chang C; Mao HQ; Sheng G; Dodge JC; Ji H; Madden S; Zack DJ; Chamling X
iScience; 2023 Mar; 26(3):106156. PubMed ID: 36852281
[TBL] [Abstract][Full Text] [Related]
13. SETD6 Regulates E2-Dependent Human Papillomavirus Transcription.
Jose L; Androphy EJ; DeSmet M
J Virol; 2022 Nov; 96(22):e0129522. PubMed ID: 36300937
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Bioinformatics Analysis Combined with Wet-Lab Experiments to Find Target Proteins of Chinese Medicine Monomer.
Xu X; Zhu Y; Yue C; Yang Q; Zhang Z
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144838
[TBL] [Abstract][Full Text] [Related]
15. Conditional Human BRD4 Knock-In Transgenic Mouse Genotyping and Protein Isoform Detection.
Lewis MP; Wu SY; Chiang CM
Bio Protoc; 2022 Apr; 12(7):. PubMed ID: 35530522
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
Kulikowski E; Rakai BD; Wong NCW
Med Res Rev; 2021 Jan; 41(1):223-245. PubMed ID: 32926459
[TBL] [Abstract][Full Text] [Related]
17. A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression.
Zhou Z; Li X; Liu Z; Huang L; Yao Y; Li L; Chen J; Zhang R; Zhou J; Wang L; Zhang QQ
Front Pharmacol; 2020; 11():1043. PubMed ID: 32765266
[TBL] [Abstract][Full Text] [Related]
18. Opposing Functions of BRD4 Isoforms in Breast Cancer.
Wu SY; Lee CF; Lai HT; Yu CT; Lee JE; Zuo H; Tsai SY; Tsai MJ; Ge K; Wan Y; Chiang CM
Mol Cell; 2020 Jun; 78(6):1114-1132.e10. PubMed ID: 32446320
[TBL] [Abstract][Full Text] [Related]
19. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
20. EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition.
Pullamsetti SS; de Jesus Perez VA
Am J Respir Crit Care Med; 2019 Nov; 200(9):1188-1190. PubMed ID: 31419389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
